FourLight-3

About this trial

The purpose of this study is to determine which study treatment combinations may work better to slow down the growth of cancer cells and shrink tumours, as well as which treatments may have fewer side effects. This study is for patients who have advanced/metastatic breast cancer who have not received any prior systemic cancer therapy for their advanced/metastatic breast cancer. The study medicine PF-07220060 is a CDK/4 inhibitor based-therapy thought to work by blocking specific growth signals within breast cancer cells, preventing the cells from growing. The study medicine, when combined with letrozole, may work as a “brake” to slow down the growth of cancer cells. Study treatments include:
1. PF-07220060 plus letrozole, or
2. Oncologist’s choice of CDK4/6 inhibitor plus letrozole.

Patient Profile

This study is for people whose breast cancer:
1. has HER2-negative breast cancer, i.e.: has a small number or no receptors for HER2.
2. has HR-positive breast cancer, i.e.: a lot of hormone receptors.
3. locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastatic disease (the spread of cancer to other places in the body).
4. who have not received any prior systemic anti-cancer treatment for advanced/metastatic disease.

Where’s this trial being run?

Beaumont Hospital, St James’s Hospital, St Vincents University Hospital, Mater Misericordiae University Hospital, and Mater Private Hospital

Can I join this study / trial?

The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.

It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

---

Summary Data

Name:	FourLight-3
Number:	25-49
Full Title:	An interventional, open-label, randomized, multicenter phase-3 study of PF-07220060 plus Letrozole compared to CDK4/6 inhibitor plus Letrozole in participants over 18 years of age with hormone receptor (HR)-positive, HER2-negative advanced/metastatic breast cancer who have not received any prior systemic anticancer treatment for advanced/metastatic disease.

Principal Investigator:	Prof Patrick Morris (Beaumont Hospital), Dr Shahid Iqbal (Mater Misericordiae University Hospital), Prof Catherine Kelly (Mater Private Hospital), Prof Janice Walshe (St Vincent's University Hospital), Dr Niamh Coleman (St James's Hospital)
Type:	Industry Sponsored
Sponsor:	Pfizer
Recruitment Started:	Global: Jan 2025 Ireland: June 2025

Global Recruitment Target:
Ireland Recruitment Target:	10